Applied Therapeutics, Inc.(APLT)Earnings, Financials & Key Ratios
APLT•NASDAQ
$0.10
$15M mkt cap·Price updated Apr 24, 2026
AboutApplied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.Show more
- Revenue$455K-95.4%
- EBITDA-$104M-61.6%
- Net Income-$106M+11.8%
- EPS (Diluted)-0.76+46.5%
- Gross Margin-10612.97%-2315.2%
- EBITDA Margin-22922.64%-3449.5%
- Operating Margin-22922.86%-3449.5%
- Net Margin-23214.07%-1837.0%
- ROE-529.97%
- Debt/Equity0.05
APLT Key Insights
Applied Therapeutics, Inc. (APLT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.3x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 6 (bottom 6%)
- ✗Shares diluted 65.6% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
APLT Price & Volume
Applied Therapeutics, Inc. (APLT) stock price & volume — 10-year historical chart
Loading chart...
APLT Growth Metrics
Applied Therapeutics, Inc. (APLT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM573.93%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM90.32%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM93.64%
Return on Capital
10 Years-221.43%
5 Years-257.99%
3 Years-363.62%
Last Year-484.59%
APLT Peer Comparison
Applied Therapeutics, Inc. (APLT) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.55B | 25.93 | -4.45 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.47B | 14.49 | -80.50 | 32.29% | -2.35% | -6.1% | 2.29 | |
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% | |||
 KRYS | 8.52B | 288.90 | 42.24 | 33.94% | 53.92% | 19.25% | 0.01 | |
 RCKT | 418.11M | 3.86 | -1.92 | -80.49% | 0.09 | |||
 MDGL | 12.38B | 539.73 | -42.00 | 432.05% | -27.32% | -50.15% | 0.59 | |
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 |
Compare APLT vs Peers
Applied Therapeutics, Inc. (APLT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
APLT Income Statement
Applied Therapeutics, Inc. (APLT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 9.99M | 455K | 1M |
| Revenue Growth % | - | - | - | - | - | - | - | -95.45% | 573.93% |
| Cost of Goods Sold | 0 | 0 | 23K | 0 | 0 | 441K | 53.91M | 48.74M | 29.45M |
| COGS % of Revenue | - | - | - | - | - | - | 539.43% | 10712.97% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -23K▲ 0% | 0▲ 100.0% | 0▲ 0% | -441K▲ 0% | -43.91M▼ 9857.4% | -48.29M▼ 10.0% | -28.45M▲ 0% |
| Gross Margin % | - | - | - | - | - | - | -439.43% | -10612.97% | -2845.5% |
| Gross Profit Growth % | - | - | - | 100% | - | - | -9857.37% | -9.97% | - |
| Operating Expenses | 4.29M | 13.52M | 45.56M | 94.47M | 105.62M | 82.51M | 20.62M | 56.01M | 69.95M |
| OpEx % of Revenue | - | - | - | - | - | - | 206.37% | 12309.89% | - |
| Selling, General & Admin | 582K | 2.05M | 13.21M | 32.68M | 43.05M | 27.32M | 20.62M | 56.01M | 61.56M |
| SG&A % of Revenue | - | - | - | - | - | - | 206.37% | 12309.89% | - |
| Research & Development | 3.7M | 11.47M | 32.35M | 61.79M | 62.57M | 55.63M | 53.91M | 48.74M | 39.06M |
| R&D % of Revenue | - | - | - | - | - | - | 539.43% | 10712.97% | - |
| Other Operating Expenses | 0 | 0 | 0 | 1 | 0 | -441K | -53.91M | -48.74M | -4M |
| Operating Income | -4.29M▲ 0% | -13.52M▼ 215.5% | -45.58M▼ 237.2% | -94.47M▼ 107.2% | -105.62M▼ 11.8% | -82.95M▲ 21.5% | -64.53M▲ 22.2% | -104.3M▼ 61.6% | -98.4M▲ 0% |
| Operating Margin % | - | - | - | - | - | - | -645.8% | -22922.86% | -9840.3% |
| Operating Income Growth % | - | -215.47% | -237.19% | -107.24% | -11.81% | 21.46% | 22.2% | -61.62% | - |
| EBITDA | 0 | 0 | -45.56M | -94.47M | -105.62M | -82.51M | -64.53M | -104.3M | -98.29M |
| EBITDA Margin % | - | - | - | - | - | - | -645.79% | -22922.64% | -9829.13% |
| EBITDA Growth % | - | - | - | -107.35% | -11.8% | 21.88% | 21.79% | -61.62% | -6.78% |
| D&A (Non-Cash Add-back) | 4.29M | 13.52M | 23K | 0 | 1.33K | 441K | 1K | 1K | 111.75K |
| EBIT | -4.28M | -14.88M | -45.51M | -94.47M | -105.62M | -82.51M | -64.53M | -104.3M | -100.64M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 685K | 1.37M | 3.53M | 2.09M |
| Interest Income | 0 | 0 | 93K | 559K | 555K | 685K | 1.37M | 3.53M | 2.09M |
| Interest Expense | 0 | 0 | 93K | 559K | 555K | 0 | 0 | 0 | 0 |
| Other Income/Expense | 3K | -3M | 69K | 505K | 34K | 442K | -55.23M | -1.32M | 80.27M |
| Pretax Income | -4.28M▲ 0% | -16.52M▼ 285.8% | -45.51M▼ 175.5% | -93.96M▼ 106.4% | -105.58M▼ 12.4% | -82.51M▲ 21.9% | -119.76M▼ 45.2% | -105.62M▲ 11.8% | -18.14M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - | -1198.47% | -23214.07% | -1813.8% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.28M▲ 0% | -16.52M▼ 285.8% | -45.51M▼ 175.5% | -93.96M▼ 106.4% | -105.58M▼ 12.4% | -82.51M▲ 21.9% | -119.76M▼ 45.2% | -105.62M▲ 11.8% | -18.14M▲ 0% |
| Net Margin % | - | - | - | - | - | - | -1198.47% | -23214.07% | -1813.8% |
| Net Income Growth % | - | -285.82% | -175.49% | -106.45% | -12.37% | 21.86% | -45.15% | 11.81% | 90.32% |
| Net Income (Continuing) | -4.28M | -16.52M | -45.51M | -93.96M | -105.58M | -82.51M | -119.76M | -105.62M | -18.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.47▲ 0% | -1.80▼ 283.0% | -3.55▼ 97.2% | -4.28▼ 20.6% | -4.12▲ 3.7% | -2.18▲ 47.1% | -1.42▲ 34.9% | -0.76▲ 46.5% | -0.12▲ 0% |
| EPS Growth % | - | -282.98% | -97.22% | -20.56% | 3.74% | 47.09% | 34.86% | 46.48% | 93.64% |
| EPS (Basic) | -0.47 | -1.80 | -3.55 | -4.28 | -4.12 | -2.18 | -1.42 | -0.76 | - |
| Diluted Shares Outstanding | 9.16M | 9.16M | 12.83M | 21.97M | 25.6M | 37.83M | 84.24M | 139.53M | 145.56M |
| Basic Shares Outstanding | 9.16M | 9.16M | 12.83M | 21.97M | 25.6M | 37.83M | 84.24M | 139.53M | 145.56M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
APLT Balance Sheet
Applied Therapeutics, Inc. (APLT) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 3.29M | 20.25M | 46.16M | 102.59M | 88.39M | 37.31M | 54.39M | 83.65M | 31.65M |
| Cash & Short-Term Investments | 3.28M | 18.75M | 38.85M | 96.83M | 80.82M | 30.58M | 49.9M | 79.4M | 11.95M |
| Cash Only | 3.28M | 18.75M | 18.85M | 57.47M | 53.89M | 16.66M | 49.9M | 79.4M | 11.95M |
| Short-Term Investments | 0 | 0 | 20M | 39.36M | 26.93M | 13.92M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 505K | 0 | 275K | 285K | 0 | 16.65M |
| Days Sales Outstanding | - | - | - | - | - | - | 10.41 | - | 1.52K |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 3.28M | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | 22.23 | - | - |
| Other Current Assets | 0 | 388K | 5.87M | 1.74M | 5.01M | 1.8M | -434K | 461K | 255K |
| Total Non-Current Assets | 0 | 0 | 2.23M | 1.91M | 1.5M | 1.05M | 447K | 3.04M | 2.72M |
| Property, Plant & Equipment | 0 | 0 | 2.04M | 1.91M | 1.3M | 1.05M | 447K | 2.79M | 2.47M |
| Fixed Asset Turnover | - | - | - | - | - | - | 22.36x | 0.16x | 0.38x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 199K | 0 | 200K | 0 | 0 | 253K | 1.01M |
| Total Assets | 3.29M▲ 0% | 20.25M▲ 516.1% | 48.39M▲ 139.0% | 104.51M▲ 116.0% | 89.89M▼ 14.0% | 38.36M▼ 57.3% | 54.83M▲ 42.9% | 86.69M▲ 58.1% | 34.37M▲ 0% |
| Asset Turnover | - | - | - | - | - | - | 0.18x | 0.01x | 0.02x |
| Asset Growth % | - | 516.13% | 139.01% | 115.97% | -13.98% | -57.32% | 42.93% | 58.1% | -142.79% |
| Total Current Liabilities | 993K | 4.43M | 14.1M | 21.23M | 26.46M | 33.42M | 71.18M | 27.3M | 32.9M |
| Accounts Payable | 713K | 3.02M | 8.79M | 640K | 9.46M | 4.53M | 1.74M | 4.43M | 4.8M |
| Days Payables Outstanding | - | - | 139.54K | - | - | 3.75K | 11.8 | 33.19 | 58.74 |
| Short-Term Debt | 0 | 0 | 0 | 1.07M | 789K | 622K | 310K | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 667K | 212K | 848K |
| Other Current Liabilities | 0 | 110K | 264K | 2.66M | 987K | 25.49M | 56.17M | 6.92M | 7.76M |
| Current Ratio | 3.31x | 4.57x | 3.27x | 4.83x | 3.34x | 1.12x | 0.76x | 3.06x | 3.06x |
| Quick Ratio | 3.31x | 4.57x | 3.27x | 4.83x | 3.34x | 1.12x | 0.72x | 3.06x | 3.06x |
| Cash Conversion Cycle | - | - | - | - | - | - | 20.84 | - | 1.46K |
| Total Non-Current Liabilities | 6.25M | 0 | 1.68M | 1.33M | 891K | 878K | 797K | 2.39M | 2.03M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 464K | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 1.68M | 1.33M | 891K | 414K | 38K | 2.39M | 8.85M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 6.25M | 0 | 0 | 0 | 0 | 0 | 759K | 0 | 0 |
| Total Liabilities | 7.25M | 4.43M | 15.78M | 22.57M | 27.35M | 34.3M | 71.98M | 29.68M | 34.94M |
| Total Debt | 0 | 0 | 2.04M | 2.81M | 2.12M | 1.98M | 777K | 2.79M | 2.5M |
| Net Debt | -3.28M | -18.75M | -16.81M | -54.65M | -51.77M | -14.68M | -49.12M | -76.6M | -9.45M |
| Debt / Equity | - | - | 0.06x | 0.03x | 0.03x | 0.49x | - | 0.05x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | 0.10x |
| Interest Coverage | - | - | -490.13x | -168.99x | -190.30x | - | - | - | - |
| Total Equity | -3.96M▲ 0% | 15.82M▲ 499.3% | 32.61M▲ 106.1% | 81.94M▲ 151.3% | 62.54M▼ 23.7% | 4.06M▼ 93.5% | -17.15M▼ 522.2% | 57.01M▲ 432.5% | -561K▲ 0% |
| Equity Growth % | - | 499.34% | 106.14% | 151.29% | -23.68% | -93.51% | -522.21% | 432.47% | 201.53% |
| Book Value per Share | -0.43 | 1.73 | 2.54 | 3.73 | 2.44 | 0.11 | -0.20 | 0.41 | -0.00 |
| Total Shareholders' Equity | -3.96M | 15.82M | 32.61M | 81.94M | 62.54M | 4.06M | -17.15M | 57.01M | -561K |
| Common Stock | 0 | 0 | 1K | 2K | 3K | 5K | 8K | 35K | 35K |
| Retained Earnings | -4.74M | -21.26M | -66.77M | -160.73M | -266.31M | -348.82M | -468.59M | -574.21M | -636.36M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -2K | -112K | -107K | 51K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
APLT Cash Flow Statement
Applied Therapeutics, Inc. (APLT) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -3.19M | -11.18M | -36.31M | -78.21M | -90.73M | -78.09M | -55.17M | -84.31M | -84.31M |
| Operating CF Margin % | - | - | - | - | - | - | -552.12% | -18528.57% | - |
| Operating CF Growth % | - | -249.98% | -224.69% | -115.41% | -16.01% | 13.93% | 29.35% | -52.8% | -34.81% |
| Net Income | -4.28M | -16.52M | -45.51M | -93.96M | -105.58M | -82.51M | -119.76M | -105.62M | -18.14M |
| Depreciation & Amortization | 0 | 0 | 23K | 380K | 415K | 443K | 354K | 425K | 405K |
| Stock-Based Compensation | 32K | 272K | 6.17M | 0 | 11.18M | 9.6M | 7.36M | 13.47M | 11.84M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 486K | 3M | -218K | 10.22M | -404K | 3.21M | 58.32M | 4.91M | -78.61M |
| Working Capital Changes | 569K | 2.06M | 3.23M | 5.15M | 3.67M | -8.84M | -1.44M | 2.52M | -2.33M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 499K | 2.3M | 5.75M | -8.04M | 8.82M | -4.93M | -2.79M | 2.69M | 1.89M |
| Cash from Investing | 0 | 0 | -20.01M | -19.47M | 12.43M | 13.17M | 13.87M | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 6.47M | 26.65M | 56.41M | 136.29M | 74.72M | 27.69M | 74.54M | 113.81M | -75K |
| Debt Issued (Net) | 0 | 5.56M | 0 | -2.15M | -4.72M | -3.27M | -1.86M | -311K | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | -1K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -2.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -72K | -2.27M | 2.73M | 5.01M | 3.15M | 11.89M | 9.37M | -74K |
| Net Change in Cash | 3.27M▲ 0% | 15.47M▲ 372.4% | 102K▼ 99.3% | 38.62M▲ 37758.8% | -3.58M▼ 109.3% | -37.23M▼ 940.6% | 33.24M▲ 189.3% | 29.5M▼ 11.3% | -86.92M▲ 0% |
| Free Cash Flow | -3.19M▲ 0% | -11.18M▼ 250.0% | -36.31M▼ 224.7% | -78.21M▼ 115.4% | -90.73M▼ 16.0% | -78.09M▲ 13.9% | -55.17M▲ 29.3% | -84.31M▼ 52.8% | -86.85M▲ 0% |
| FCF Margin % | - | - | - | - | - | - | -552.12% | -18528.57% | -8684.7% |
| FCF Growth % | - | -249.98% | -224.69% | -115.41% | -16.01% | 13.93% | 29.35% | -52.8% | -6.12% |
| FCF per Share | -0.35 | -1.22 | -2.83 | -3.56 | -3.54 | -2.06 | -0.65 | -0.60 | -0.60 |
| FCF Conversion (FCF/Net Income) | 0.75x | 0.68x | 0.80x | 0.83x | 0.86x | 0.95x | 0.46x | 0.80x | 4.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
APLT Key Ratios
Applied Therapeutics, Inc. (APLT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -278.67% | -187.97% | -164.06% | -146.16% | -247.77% | - | -529.97% | -65.63% |
| Return on Invested Capital (ROIC) | - | -531.42% | -328.91% | -416.28% | -80795.45% | - | - | 574.58% |
| Gross Margin | - | - | - | - | - | -439.43% | -10612.97% | -2845.5% |
| Net Margin | - | - | - | - | - | -1198.47% | -23214.07% | -1813.8% |
| Debt / Equity | - | 0.06x | 0.03x | 0.03x | 0.49x | - | 0.05x | 0.05x |
| Interest Coverage | - | -490.13x | -168.99x | -190.30x | - | - | - | - |
| FCF Conversion | 0.68x | 0.80x | 0.83x | 0.86x | 0.95x | 0.46x | 0.80x | 4.79x |
| Revenue Growth | - | - | - | - | - | - | -95.45% | 573.93% |
APLT Frequently Asked Questions
Applied Therapeutics, Inc. (APLT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Applied Therapeutics, Inc. (APLT) reported $1.0M in revenue for fiscal year 2024.
Applied Therapeutics, Inc. (APLT) saw revenue decline by 95.4% over the past year.
Applied Therapeutics, Inc. (APLT) reported a net loss of $18.1M for fiscal year 2024.
Dividend & Returns
Applied Therapeutics, Inc. (APLT) has a return on equity (ROE) of -530.0%. Negative ROE indicates the company is unprofitable.
Applied Therapeutics, Inc. (APLT) had negative free cash flow of $86.8M in fiscal year 2024, likely due to heavy capital investments.
Explore More APLT
Applied Therapeutics, Inc. (APLT) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates